Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

David Wallace

Executive Editor

Generics Bulletin Executive Editor Dave Wallace has more than 10 years' experience of reporting on the global generics, biosimilars and value-added medicines industries. Having begun his career in the European chemicals industry, Dave has now spent over a decade with Generics Bulletin, becoming editor from 2018. Bringing his background and education in law to bear on industry litigation as well as national legislative and regulatory affairs, he also keeps a close eye on corporate strategy, personnel moves, and product pipelines. A regular delegate to industry events and conferences, he has a particular interest in local market developments, maintaining close links with national industry representatives. He also organizes and acts as a judge for the annual Global Generics & Biosimilars Award.

Latest From David Wallace

EU Industry Decries Price Cuts And Clawbacks

A detailed report published by Medicines for Europe setting out policies affecting the off-patent industry across 22 European countries demonstrates the urgent need for pricing and reimbursement and procurement reforms, the association insists.

Europe Policy & Regulation

180 Life Sciences Is Looking To Repurpose Biosimilars

US firm 180 Life Sciences believes that existing anti-TNF biologics have the potential to address a variety of other conditions in which patients currently have unmet needs. CEO Dr Jim Woody tells Generics Bulletin about how the company is exploring new indications for off-patent biologics.

Biosimilars Strategy

Entries Open For The Global Generics & Biosimilars Awards 2021

Entries are now open for the Global Generics & Biosimilars Awards 2021, which will take place in Milan, Italy on 10 November.

Generic Drugs Biosimilars

Australia’s Manufacturing Road Map Wins Plaudits From Industry

A medicines manufacturing “road map” set out by Australia’s government has the backing of the local off-patent industry.

Manufacturing Policy

EU ‘Structured Dialog’ Offers Opportunity To Secure Supply

A “structured dialog” led by the European Commission with pharmaceutical industry stakeholders provides a critical opportunity to address weaknesses in the stability and security of the supply chain by improving the environment for local manufacturing, Medicines for Europe believes.

Manufacturing Europe

Formycon And Bioeq Offer Ranibizumab Update

Formycon and partner Bioeq have offered further details on timing for the submission of their FYB201 proposed ranibizumab biosimilar version of Lucentis in Europe, the US and elsewhere.

Biosimilars Strategy
See All
UsernamePublicRestriction

Register